PARI Group
PARI Group is a privately held German medical technology company founded in 1906 that designs and manufactures inhalation therapy devices (nebulizers, compressors, masks, airway clearance systems) for respiratory disease patients, distributed in 80+ countries with co-development partnerships serving pharmaceutical majors including Roche, AstraZeneca, and Genentech.
- Company typePrivate
- Founded1906
- HeadquartersStarnberg, Germany
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What PARI Group does
PARI Group is a privately held German medical technology company specializing in inhalation therapy devices for respiratory diseases. Founded in 1906 in Wuppertal and now headquartered in Starnberg, the company operates under PARI Medical Holding GmbH with 251-500 employees and subsidiaries including PARI GmbH (Germany) and PARI Respiratory Equipment, Inc. (Midlothian, Virginia). Its core products are jet-compressor and vibrating-membrane nebulizers (PARI BOY, PRONEB, Vios, eFlow, eRapid, Magnair, Lamira, VELOX), reusable and disposable nebulizer cups (LC Sprint, LC PLUS, LC STAR), age-specific aerosol masks (PARI BABY sizes 0-3, Bubbles the Fish, SMARTMASK), airway clearance devices (PARI PEP S, PARI O-PEP), and sinus therapy systems (PARI SINUS2, VibrENT), complemented by accessories and inhalation solutions such as Hypersal and Kitabis Pak. The proprietary eFlow vibrating-membrane platform is co-developed with pharmaceutical partners and is listed in FDA-approved package inserts for major respiratory drugs including TOBI (Genentech), Pulmozyme (Roche), Pulmicort Respules (AstraZeneca), DuoNeb (Mylan/Baxter), Brovana and Xopenex (Sunovion), Ohtuvayre (Chiesi), and MOLBREEVI (Savara).
Revenue is generated through two principal streams: (1) hardware sales of inhalation devices via direct B2B ordering (PARIOrder.com), pharmacy distribution in Germany and Austria, online partner stores in the US (Nebology, Just Nebulizers, Health Connection, Shop Nebulizer), and a global distributor network spanning 80+ countries; and (2) pharmaceutical partnership and licensing arrangements in which PARI's eFlow and PARI BOY platforms are validated for clinical trials and referenced in drug package inserts, generating device pull-through and co-development revenue. PARI has also begun vertical extension via the 2023 acquisition of Irish veterinary respiratory-device maker Nortev (Flexineb). Leadership comprises Dr. Stefan Seemann (CEO), Anja Zschernig (CFO), Dr. Frank Bredl (Managing Director, PARI GmbH), and Derek Kish (President, PARI Respiratory Equipment, Inc.).
PARI Group firmographics
Firmographics- Name
- PARI Group
- Legal name
- PARI Respiratory Equipment, Inc.
- Website
- https://pari.com
- Company type
- Private
- Founded year
- 1906
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- PARI Group is a privately held German medical technology company founded in 1906 that designs and manufactures inhalation therapy devices (nebulizers, compressors, masks, airway clearance systems) for respiratory disease patients, distributed in 80+ countries with co-development partnerships serving pharmaceutical majors including Roche, AstraZeneca, and Genentech.
- Ownership category
- akta.pro rank
PARI Group industry classification
Industry- Product category
- Respiratory Inhalation Therapy Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE)
- akta.pro secondary industries
- Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ), Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters) (HLAHAGAG), Respiratory & Sleep Therapy Equipment (Oxygen, CPAP/BiPAP, Nebulizers) (HSABAKAD)
Keywords
Where PARI Group is headquartered
LocationHeadquarters
- HQ city
- Starnberg
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
PARI Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Hardware Sales: PARI generates revenue through the sale of inhalation therapy devices including nebulizers, compressors, aerosol masks, holding chambers, and airway clearance devices. Products are sold directly to patients, through distributors, pharmacies, and medical supply retailers.
- Pharmaceutical Partnership and Licensing: PARI partners with pharmaceutical companies to provide optimized nebulizer systems for drug delivery. Products are listed in package inserts for approved medications, generating revenue through partnership arrangements for clinical trials and commercialization.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
PARI Group product offering
Product offeringCore offering
PARI Group designs, manufactures, and sells inhalation therapy medical devices — including jet and vibrating-membrane nebulizers, compressors, reusable and disposable nebulizer cups, aerosol masks for neonatal through adult patients, airway clearance devices, holding chambers, and inhalation solutions — used in the treatment of asthma, COPD, cystic fibrosis, bronchitis, sinusitis, and bronchiolitis. The company also develops its proprietary eFlow vibrating-membrane nebulizer platform for co-development with pharmaceutical partners, with PARI devices listed in package inserts for FDA-approved respiratory drugs.
Product overview
PARI is a medical technology company specializing in inhalation therapy devices for respiratory diseases. The product portfolio is organized into several interconnected categories: jet nebulizer systems (PRONEB, Vios, PARI BOY, PARI COMPACT, SINUS2, TREK), vibrating membrane nebulizer systems (eFlow, eRapid, Magnair, Zirela, Lamira, VELOX), nebulizer cups/reusable and disposable variants (LC, LC PLUS, LC STAR, LC Sprint), masks for different age groups (Adult Aerosol Mask, PARI Bubbles Pediatric Mask, PARI BABY masks in 4 sizes, SMARTMASK), airway clearance devices (PARI PEP S, PARI O-PEP), holding chambers/spacers (VORTEX), accessories (Filter/Valve Set, Wing Tip Tubing, Filter Pads, PEP Monitor, KIDS Kit, incentive stickers), and inhalation solutions (Hypersal, Kitabis Pak). The company also offers eFlow Technology as a pharmaceutical partnering platform for optimized membrane nebulizers. Products serve respiratory conditions including asthma, COPD, cystic fibrosis, bronchitis, sinusitis, and bronchiolitis. PARI operates with a direct-to-patient online ordering platform (PARIOrder.com for B2B and online dealer partners for patients), maintains distribution in over 80 countries, and conducts clinical trials with major pharmaceutical partners including products in package inserts for TOBI, Pulmozyme, and Cayston.
Differentiator
Problem solved
Functional benefit
Brands
- PRONEB: Compressor-based nebulizer delivery system
- eFlow
- PARI BOY
- PARI COMPACT2
- PARI SINUS2
- VELOX
- VORTEX
- PARI LC Sprint
- PARI PEP
- BUBBLES THE FISH
- PARI BABY
Products and services
- PRONEB Max Aerosol Delivery System Aerosol delivery system with a sleek design and lower operating temperature, capable of handling multiple treatments per day for patients with respiratory conditions.
- Vios Aerosol Delivery System Aerosol delivery system for respiratory therapy in clinical and home settings.
- Vios PRO Aerosol Delivery System Professional-grade aerosol delivery system for clinical and home use in respiratory therapy.
- PARI TREK Compact Compressor Portable compact compressor for inhalation therapy, designed for mobility and on-the-go use.
- PARI TREK S Compact Compressor Compact compressor for inhalation therapy with mobility features for travel and active patients.
- PARI BOY Nebulizer System Reliable, robust nebulizer system available in Junior, Classic, and Pro variants with variable droplet spectrum for different patient needs — from babies and toddlers to adults with acute and chronic respiratory diseases.
- PARI COMPACT2 Inhalation Device Compact inhalation device proven effective in the treatment of diseases of the lower airways.
- PARI SINUS2 Pulsating Aerosol Device Pulsating aerosol inhalation device for the treatment of sinusitis.
- eFlow Vibrating Membrane Nebulizer Platform Vibrating membrane nebulizer technology platform developed in cooperation with pharmaceutical partners for optimized delivery of innovative inhaled medications; basis for drug-device combinations listed in FDA-approved package inserts.
- eRapid Nebulizer System Fast-acting vibrating membrane nebulizer system for efficient aerosol delivery of inhaled medications.
- VELOX Mobile Nebulizer Mobile vibrating membrane nebulizer for particularly fast and quiet inhalation, designed for on-the-go use.
- PARI LC Sprint Reusable Nebulizer Reusable nebulizer cup with optimized droplet spectrum for fast, effective inhalation therapy.
- PARI LC PLUS Reusable Nebulizer Reusable nebulizer cup with enhanced performance characteristics for aerosol inhalation therapy.
- PARI LC STAR Reusable Nebulizer Star-configured reusable nebulizer cup for targeted aerosol delivery with specific droplet spectrum.
- PARI LC D Disposable Nebulizer Disposable nebulizer cup designed for single or limited use in clinical or infection-control settings.
- PARI BABY Mask Size 0 Aerosol mask designed for neonates up to 1 month old, supporting the low inspiratory flow rate and small tidal volumes of newborns.
- PARI BABY Mask Size 1 Aerosol mask for infants aged 1–11 months.
- PARI BABY Mask Size 2 Aerosol mask for toddlers aged 1–3 years.
- PARI BABY Mask Size 3 Aerosol mask for children aged 3+ years.
- PARI Bubbles Pediatric Aerosol Mask Pediatric aerosol mask with Pro-Vent technology designed for children ages 3+, featuring a fun fish character design to encourage treatment adherence.
- Adult Aerosol Mask Adult aerosol mask with Pro-Vent technology for patients unable to use a mouthpiece, delivering more medication while reducing facial and eye deposition during nebulizer treatments.
- VORTEX Non-Electrostatic Valved Holding Chamber Non-electrostatic valved holding chamber that reduces static charge to improve aerosol delivery efficiency from metered-dose inhalers.
- PARI PEP S Airway Clearance Device Positive Expiratory Pressure device offering both traditional PEP therapy and combination PEP/nebulizer therapy, with eight resistance settings covering expiratory pressure of 10–20 cm H2O.
- PARI O-PEP Oscillating Airway Clearance Device Oscillating Positive Expiratory Pressure device producing vibration transmitted to the lungs, with adjustable oscillation frequencies between 6 and 20 Hz for mucus clearance in cystic fibrosis and secretory lung disease patients.
- PARI Filter/Valve Set Filter set designed to reduce the release of exhaled aerosol into the environment during nebulizer treatments, reducing nebulized solution escaping into the surroundings to less than 1%.
- PARI Montesol Nasal Wash Nasal wash solution for sinus irrigation as part of respiratory therapy regimens.
- Hypersal Hypertonic Saline Inhalation Solution Hypertonic saline inhalation solution for respiratory therapy.
- Kitabis Pak Tobramycin Inhalation Solution Pre-packaged tobramycin inhalation solution for cystic fibrosis patients.
- Flexineb Equine Nebuliser Respiratory therapy device for horses and companion animals, manufactured by Nortev (acquired by PARI in May 2023) and leveraging PARI's inhalation therapy expertise for veterinary applications.
Quantifiable outcome
- PARI products are used in more clinical trials than any other nebulizer brand
- +1 more outcomes
Companies that use PARI Group
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
PARI Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
PARI Group partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- SavaracorePARI and Savara were granted a European patent for the drug-device combination of MOLBREEVI delivered via the PARI eFlow Nebulizer System. The partnership supports MOLBREEVI's long-term protection and planned regulatory submissions for autoimmune pulmonary alveolar proteinosis (PAP) treatment.
- NortevcorePARI acquired Irish company Nortev, which manufactures the equine nebuliser Flexineb, a respiratory therapy device for horses and companion animals. The acquisition aims to leverage PARI's inhalation therapy experience to develop new veterinary respiratory treatments and expand Nortev's market presence.
- Pharmaceutical Companies (Roche, AstraZeneca, Genentech, Chiesi, Sunovion, Mylan)corePARI products are used in clinical trials and listed in package inserts for multiple FDA-approved respiratory medications including Pulmozyme, Pulmicort Respules, TOBI, DuoNeb, Xopenex, Brovana, and Ohtuvayre.
Scale indicators3 records
Recent moves5 records
Expansion highlights6 records
PARI Group competitors and assessment
Company assessmentDirect peers
- Drive DeVilbiss Healthcare: Manufactures a broad portfolio of jet nebulizers, compressors, and respiratory consumables for home and clinical use. Competes head-to-head with PARI in DME and pharmacy distribution.
- Vyaire Medical: Pure-play respiratory diagnostics and ventilation company offering nebulizers, spirometry, and airway clearance. Comparable product overlap with PARI's hospital and home-care franchises.
- Omron Healthcare: Markets compressor nebulizers (NE-C801, NE-U100 mesh) for home respiratory therapy. Direct competitor to PARI's PRONEB and PARI BOY lines in retail and pharmacy channels.
- Aerogen: Specialist in vibrating mesh aerosol drug delivery for hospital and intensive care settings. Closest technology analog to PARI's eFlow platform, with strong pharma partnership model for inhaled drugs.
Broad incumbents
- Philips Respironics: Respiratory care division of Royal Philips offering nebulizers, CPAP/BiPAP, oxygen concentrators, and hospital ventilation. Directly comparable to PARI in jet and mesh nebulization plus broader sleep and ventilation franchises.
- ResMed: Global leader in sleep and respiratory care with connected CPAP, ventilators, and growing nebulizer-adjacent offerings. Comparable to PARI in targeting chronic respiratory patients with hardware-plus-digital ecosystems.
- Fisher & Paykel Healthcare: Specialist in respiratory humidification, neonatal care, and OSA therapy. Comparable to PARI in hospital respiratory consumables and patient-adjacent chronic care markets.
- Becton, Dickinson and Company (BD): Diversified medical technology company with pharmaceutical systems and drug delivery device franchises. Comparable to PARI's eFlow partnering model for injectable and inhaled drug delivery partnerships.
- Medline Industries: Major medical supply manufacturer and distributor with respiratory therapy product lines including nebulizers. Comparable distribution scale and DME-channel presence to PARI.
- Teleflex (Respiratory division): Offers aerosol drug delivery and airway management products. Overlaps with PARI's hospital-channel nebulizer and airway clearance segments.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
PARI Group social profiles
Digital presencePARI Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
PARI Group leadership team
Management profileNumber of profiles
Profiles4 records
PARI Group subsidiaries and ownership
Company hierarchySubsidiaries1 record
PARI Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PARI Group M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PARI Group
What does PARI Group do?
PARI Group designs, manufactures, and sells inhalation therapy medical devices — including jet and vibrating-membrane nebulizers, compressors, reusable and disposable nebulizer cups, aerosol masks for neonatal through adult patients, airway clearance devices, holding chambers, and inhalation solutions — used in the treatment of asthma, COPD, cystic fibrosis, bronchitis, sinusitis, and bronchiolitis. The company also develops its proprietary eFlow vibrating-membrane nebulizer platform for co-development with pharmaceutical partners, with PARI devices listed in package inserts for FDA-approved respiratory drugs.
Is PARI Group a public or private company?
PARI Group is a private company. It is classified as family owned and is currently operating.
When was PARI Group founded?
PARI Group was founded in 1906. It employs 251 to 500 people.
Where is PARI Group based?
PARI Group is headquartered in Starnberg, Germany, in the Europe region.
How does PARI Group make money?
Two revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are pharmaceutical Partnership and Licensing.
Who are PARI Group's main competitors?
Direct peers on record are Drive DeVilbiss Healthcare, Vyaire Medical, Omron Healthcare and Aerogen. Broad incumbents are Philips Respironics, ResMed, Fisher & Paykel Healthcare, Becton, Dickinson and Company (BD), Medline Industries and Teleflex (Respiratory division).
Does PARI Group have an API?
No public API is recorded for PARI Group.
What industry is PARI Group in?
PARI Group's product category is Respiratory Inhalation Therapy Devices. Its primary akta.pro industry code is HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories), with a secondary code of HLAHAIAJ, Nebulizers & Aerosol Drug Delivery Systems. Its NAICS code is 3391 and its SIC code is 3841.